BioDelivery Sciences strengthens public relations

BioDelivery Sciences Retains The Trout Group for Investor Relations Services  June 1, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI®) (Nasdaq: BDSI) today announced that it has retained The Trout Group, a leading investor relations and strategic advisory firm, to assist in the Company's shareholder communication efforts. The Trout Group provides investor relations and advisory services principally for the life sciences industry.  Based in New York, The Trout Group has a global reach to the investment community with satellite offices in Boston, San Francisco, London and Shanghai.  The Trout Group will be assisting BioDelivery Sciences with its corporate goals, including broadening the Company's exposure to institutional investors."BDSI looks forward to partnering with The Trout Group as part of our ongoing efforts to significantly enhance our communications outreach to the investor community," stated Benny Ward, Executive Vice President of Business and Strategic Development for BDSI.  "Given important milestones forthcoming, particularly Phase 3 data for BEMA Buprenorphine for the treatment of chronic pain, we believe The Trout Group is well suited to assist us in effectively communicating our business and growth strategy as well as raise awareness of BDSI within the investment community.  We look forward to working with the team at The Trout Group as we move into this exciting period of time for the company and continue to seek to build shareholder value over the long term."

About BioDelivery Sciences International BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it will be marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.).  BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation for the treatment of opioid dependence.  Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron).  BDSI's headquarters is located in Raleigh, North Carolina.  For more information, visit www.bdsi.com.  BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL is registered trademark of Meda Pharma GmbH & Co. KG.

Cautionary Note on Forward-Looking Statements  This press release, the presentation described herein and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, results of the clinical development for and regulatory review of the Company's product candidates) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publically update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.  Readers are cautioned that peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such estimates are accurate or that such sales levels will be achieved, if at all.